Research Summaries

In a prospective study, researchers evaluated the immune response and adverse events of COVID-19 and seasonal influenza vaccine coadministration.

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.

Individuals with acute myeloid leukemia often have low levels of vitamin C and vitamin D at the time of diagnosis. Researchers examined how supplementation of these vitamins during treatment impacted...

Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.

This COVID-19 roundup includes coverage on the outcomes associated with two omicron subvariant treatments, FDA’s authorization of Novavax vaccine, the NIH Treatment Guidelines Panel’s recommendation of...

Researchers set out to determine whether DNA sequencing of the blood from adults with acute myeloid leukemia in remission before allogeneic hematopoietic cell transplant could detect residual variant...

Leading experts in the fields of cardiovascular and family medicine describe the risk factors associated with cardiovascular disease, review the strategies designed to mitigate the risk factors associated...

In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.

The FDA has approved the first biosimilar treatment for patients living with relapsing forms of multiple sclerosis.

Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.